Our approach to R&D
Harnessing the “multiplier effect”: Science x Technology x Culture
Our R&D approach aims to deliver next-generation medicines that bring the greatest value to patients.
In Pharmaceuticals, we focus on science related to the immune system, the use of human genetics and advanced technologies. Driving our R&D is the “multiplier effect” – Science x Technology x Culture – which was introduced in 2018 by Dr Hal Barron, Chief Scientific Officer and President, R&D.
This approach will help us discover, develop and deliver transformational medicines faster. It means we will prioritise molecules that have a greater chance of becoming a medicine that will improve patients’ lives.
In our Vaccines business, we balance two priorities: a pipeline of innovative candidate vaccines, and lifecycle management of our existing vaccines. Our goal is to protect more people in more geographies.
As technology and our understanding of science and the human body move forward, we will be able to explore new breakthroughs and apply them to some of the world’s biggest health challenges. We have continually pushed the boundaries in vaccine science. Our advances include the development of recombinant DNA-based vaccines as well as the introduction of a variety of adjuvant systems.
Here are the three elements of the “multiplier effect”:
Discovery and development are risky. Fewer than 10% of drugs in clinical testing become medicines.
Our R&D approach involves significant investment in advanced technologies.
Our unique culture brings our R&D to life.
Find out more about us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
Our focus areas in development
We invest in scientific and technical excellence to develop and launch a pipeline of new products in a range of focus areas
Trials in people
Clinical trials and patient
Our use of animals
At GSK we believe we have a moral responsibility to ensure good welfare and treatment of the animals in our care